(Total Views: 577)
Posted On: 03/06/2021 12:08:42 AM
Post# of 153903
Re: ClosetInvestor #81126
62 patients were critical at the time they enrolled in our s/c trial and when they were either injected with leronlimab or received only SOC.
Severe cv19 patients given SOC, are more likely to advance to critical vs severe patients given leronlimab. The severe patients given SOC who advance to critical, may be just as likely to die as those who were critical when they entered the trial and were started on SOC (placebo). So, was severe data not included in the PR because the data was bad, or because the data needs further analysis?
It seems unprofessional or evasive or misleading to not say anything in the PR about severe patient data. I really don't want to believe they intentionally left severe data out because it was bad. We will see it eventually. And why leave it out if it was good?
Severe cv19 patients given SOC, are more likely to advance to critical vs severe patients given leronlimab. The severe patients given SOC who advance to critical, may be just as likely to die as those who were critical when they entered the trial and were started on SOC (placebo). So, was severe data not included in the PR because the data was bad, or because the data needs further analysis?
It seems unprofessional or evasive or misleading to not say anything in the PR about severe patient data. I really don't want to believe they intentionally left severe data out because it was bad. We will see it eventually. And why leave it out if it was good?
(4)
(0)
